Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Blood

• Publication date

  2001-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V98.5.1416PMID 11520790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phage Display Technology: A Tool to Explore the Diversity of Inhibitors to Blood Coagulation Factor VIII

  2000cited by this paper
• Blood Coagulation Factor IX Residues Glu78 and Arg94 Provide a Link between Both Epidermal Growth Factor-like Domains That Is Crucial in the Interaction with Factor VIII Light Chain*

  1998cited by this paper
• Identification of residues in the Gla-domain of human factor IX involved in the binding to conformation specific antibodies.

  1998cited by this paper
• Comparative Analysis of Haemostatic Proteinases: Structural Aspects of Thrombin, Factor Xa, Factor IXa and Protein C

  1997cited by this paper
• Expression, purification, and characterization of recombinant human factor X.

  1997cited by this paper
• Interaction of Factor IXa with Factor VIIIa

  1997cited by this paper
• Ca2+ Binding to the First Epidermal Growth Factor-like Domain of Human Blood Coagulation Factor IX Promotes Enzyme Activity and Factor VIII Light Chain Binding*

  1996cited by this paper
• Structural Integrity of the -Carboxyglutamic Acid Domain of Human Blood Coagulation Factor IXa Is Required for Its Binding to Cofactor VIIIa (*)

  1996cited by this paper
• Detection of bilayer phospholipid‐binding antibodies using flow cytometry

  1996cited by this paper
• Identification of the Phospholipid Binding Site in the Vitamin K-dependent Blood Coagulation Protein Factor IX*

  1996cited by this paper
• Localization of a calcium-dependent epitope to the amino terminal region of the Gla domain of human factor IX.

  1996cited by this paper
• Crystallographic studies of antigen-antibody interactions.

  1996cited by this paper
• Gene mutations and inhibitor formation in patients with hemophilia B.

  1995influential reference
• Structure of the Metal-free γ-Carboxyglutamic Acid-rich Membrane Binding Region of Factor IX by Two-dimensional NMR Spectroscopy (*)

  1995cited by this paper
• Cleavage at Arginine 145 in Human Blood Coagulation Factor IX Converts the Zymogen into a Factor VIII Binding Enzyme (*)

  1995cited by this paper
• Retrospective study of inhibitor formation in Japanese hemophiliacs.

  1995cited by this paper
• Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX.

  1995cited by this paper
• Localization of Factor IXa and Factor VIIIa Interactive Sites (*)

  1995cited by this paper
• In Vitro Mutagenesis Study of Two Critical Glutamic Acids in the Calcium Binding Loop of the Factor IX Heavy Chain

  1994cited by this paper
• Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII.

  1994cited by this paper
• Epitope mapping of human factor IX inhibitor antibodies

  1994cited by this paper
• Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study.

  1992cited by this paper
• Prevalence of Inhibitors in a Population of 3435 Hemophilia Patients in France

  1992cited by this paper
• Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain.

  1992cited by this paper
• Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors.

  1991cited by this paper
• Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

  1990cited by this paper
• Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.

  1989cited by this paper
• Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

  1989cited by this paper
• Dot-immunobinding assay as an accurate and versatile technique for the quantification of human IgG subclasses.

  1988cited by this paper
• The role of beta‐hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor IX.

  1988cited by this paper
• Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time.

  1988cited by this paper
• Immunogenic and antigenic epitopes of immunoglobulin--XX. Denaturation of human IgG3 by free radicals.

  1987cited by this paper
• Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation.

  1987cited by this paper
• Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C.

  1986cited by this paper
• Nucleotide sequence of the gene for human factor IX (antihemophilic factor B).

  1985cited by this paper
• The contribution of Ca2+ and phospholipids to the activation of human blood-coagulation Factor X by activated Factor IX.

  1984cited by this paper
• Evaluation of Thirty-One Mouse Monoclonal Antibodies to Human IgG Epitopes

  1984cited by this paper
• Inhibitors in Christmas disease.

  1984cited by this paper
• Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium.

  1984cited by this paper
• Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

  1978cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Proceedings: A more uniform measurement of factor VIII inhibitors.

  1975cited by this paper

• F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B

  2022cites this paper
• Plasma factor IX: The tip of the iceberg?

  2021cites this paper
• Probing activation‐driven changes in coagulation factor IX by mass spectrometry

  2021cites this paper
• Laboratory Monitoring of Factor VIII and Factor IX in Hemophilia Patients

  2019cites this paper
• Hemophilia B

  2019cites this paper
• Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B

  2019cites this paper
• A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A

  2019cites this paper
• Novel assays in the coagulation laboratory: a clinical and laboratory perspective.

  2018cites this paper
• Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review

  2018cites this paper
• Inhibitors in Hemophilia B

  2018cites this paper
• Survey of the anti–factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence‐based immunoassay

  2016cites this paper
• Advances in the clinical management of inhibitors in hemophilia A and B.

  2016cites this paper
• The carboxyl‐terminal region is NOT essential for secreted and functional levels of coagulation factor X

  2015cites this paper
• Inhibitors to factor VII and in congenital factor VII deficiency

  2014cites this paper
• Plasma Components as Targets of Damage

  2014cites this paper
• transduction of murine and nonhuman primate liver efficient liver-specific human factor IX expression cassette enable highly Self-complementary adeno-associated virus vectors containing a novel

  2013cites this paper
• Chapter 107 – Hemophilia B

  2013cites this paper
• Animal models of hemophilia.

  2012cites this paper
• Les anticorps anti-FVIII et anti-FIX

  2012cites this paper
• Immune tolerance in haemophilia: the long journey to the fork in the road

  2012influential citation
• Proteolytic antibodies activate factor IX in patients with acquired hemophilia.

  2011cites this paper
• Immune tolerance induction in haemophilia: evidence and the way forward

  2011cites this paper
• Immune tolerance induction in haemophilia: evidence and the way forward.

  2011cites this paper
• Inhibitors to Factor VIII/IX: Immune Tolerance

  2010cites this paper
• Treatment of Inhibitors in Hemophilia B

  2010cites this paper
• Use of a Bacterially Expressed Human Factor IX Light Chain to Develop Polyclonal Antibody Anti-hFIX

  2009cites this paper
• Dérivés de protéases à sérine et leurs utilisations dans la prévention ou le traitement de troubles de la coagulation du sang

  2009cites this paper
• Factor IX: Insights from knock-out and genetically engineered mice

  2008cites this paper
• Inhibitor development in haemophilia B: an orphan disease in need of attention

  2007cites this paper
• Role of the alpha-helix 163-170 in factor Xa catalytic activity.

  2007cites this paper
• Role of the α-Helix 163-170 in Factor Xa Catalytic Activity*

  2007cites this paper
• The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation.

  2006cites this paper
• Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.

  2006cites this paper
• Basic aspects of inhibitors to factors VIII and IX and the influence of non‐genetic risk factors

  2006cites this paper
• Factor IX Deficiency

  2005cites this paper
• Mapping of genes that control the antibody response to human factor IX in mice.

  2005cites this paper
• Pathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IX

  2004cites this paper
• Role of the Gla and First Epidermal Growth Factor-like Domains of Factor X in the Prothrombinase and Tissue Factor-Factor VIIa Complexes*

  2003cites this paper
• Residues Phe342–Asn346 of Activated Coagulation Factor IX Contribute to the Interaction with Low Density Lipoprotein Receptor-related Protein*

  2003cites this paper